Objective: to reduce the cost of Roche cobase801 luminescent reagent used in the department and study the feasibility of combining the residual reagents of seven different Roche tumor markers. Methods: the sera of 20 ...Objective: to reduce the cost of Roche cobase801 luminescent reagent used in the department and study the feasibility of combining the residual reagents of seven different Roche tumor markers. Methods: the sera of 20 hospitalized patients on the same day were collected, and 3-4 reagent bottle of the same item and batch number with reagent interface test number of 0 were collected and mixed into 1 bottle. The results of 20 samples of new reagents and mixed reagents were tested on Roche cobase801, and the test results of the two reagents were compared and analyzed. The quality control of original new reagents and combined reagents was monitored simultaneously using Roches tumor marker controls, PreciControlTumorMarkerLevel1 and PreciControlTumorMarkerLevel2. Results: by detecting AFP (alpha-fetoprotein) \TPSA (total prostate specific antigen) \CEA (carcinoembryonic antigen) \CA19-9 (carbohydrate antigen 19-9)\FPSA (free prostate specific antigen) \CA125 (carbohydrate antigen 125)\CA15-3 (carbohydrate antigen 15-3), there was no significant difference between the remaining combined reagent and the original new reagent (p > 0.05). The quality control of the combined reagent with the remaining amount is under control. Conclusion: the residual reagents of Roche cobase801 are well preserved. After 3-4 boxes of the same batch of residual reagents are combined, the quality control can be used as the original reagents under controlled conditions, which can ensure the accuracy of detection results.展开更多
文摘Objective: to reduce the cost of Roche cobase801 luminescent reagent used in the department and study the feasibility of combining the residual reagents of seven different Roche tumor markers. Methods: the sera of 20 hospitalized patients on the same day were collected, and 3-4 reagent bottle of the same item and batch number with reagent interface test number of 0 were collected and mixed into 1 bottle. The results of 20 samples of new reagents and mixed reagents were tested on Roche cobase801, and the test results of the two reagents were compared and analyzed. The quality control of original new reagents and combined reagents was monitored simultaneously using Roches tumor marker controls, PreciControlTumorMarkerLevel1 and PreciControlTumorMarkerLevel2. Results: by detecting AFP (alpha-fetoprotein) \TPSA (total prostate specific antigen) \CEA (carcinoembryonic antigen) \CA19-9 (carbohydrate antigen 19-9)\FPSA (free prostate specific antigen) \CA125 (carbohydrate antigen 125)\CA15-3 (carbohydrate antigen 15-3), there was no significant difference between the remaining combined reagent and the original new reagent (p > 0.05). The quality control of the combined reagent with the remaining amount is under control. Conclusion: the residual reagents of Roche cobase801 are well preserved. After 3-4 boxes of the same batch of residual reagents are combined, the quality control can be used as the original reagents under controlled conditions, which can ensure the accuracy of detection results.
